Seguridad cardiovascular de Glimepirida vs. Linagliptina

Areas terapeuticas

• Cardiometabolico

Contenido

Las enfermedades cardiovasculares inducidas por la diabetes mellitus (DM) afectan tanto los lechos microvasculares como macrovasculares de todo el cuerpo humano. De hecho, la enfermedad macrovascular resulta en varios trastornos cardiovasculares:¹

Las enfermedades cardiovasculares (ECV) representan la mayoría de la mortalidad relacionada con la DM1.¹

Referencias

1. Pappachan J. M. (2021). Efficacy and Cardiovascular Safety of Antidiabetic Medications. Current drug safety, 16(2), 115–121. https://doi.org/10.2174/1574886316666210112153429
2. John, M., Kalra, S., & Nair, T. (2020). Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?. Indian heart journal, 72(4), 312–315. https://doi.org/10.1016/j.ihj.2020.07.009
3. Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., Mocarelli, P., Lucisano, G., Sacco, M., Signorini, S., Cappellini, F., Perriello, G., Babini, A. C., Lapolla, A., Gregori, G., Giordano, C., … Italian Diabetes Society (2017). Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The lancet. Diabetes & endocrinology, 5(11), 887–897. https://doi.org/10.1016/S2213-8587(17)30317-0
4. Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., Meinicke, T., George, J. T., von Eynatten, M., McGuire, D. K., Marx, N., & CAROLINA Investigators (2019). Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA, 322(12), 1155–1166. https://doi.org/10.1001/jama.2019.13772